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Abstract 
Purpose: To investigate the relationship between prognosis of gastric cancer (GC) and the expression 
of P53, Epidermal growth factor receptor (EGFR), Human epidermal growth factor receptor-2 (HER-2), 
and Vascular endothelial growth factor (VEGF).  
Methods: One hundred and forty-seven patients admitted to People's Liberation Army General Hospital 
(Beijing, China) with diagnosis of locally advanced GC were enrolled in the study. Follow-up data were 
obtained by outpatient review or telephone follow-up. Expressions of P53, EGFR, HER-2 and VEGF 
were determined by immunohistochemical staining. The relationship between protein expression, 
clinico-pathological factors, disease-free survival time (DFS) and overall survival (OS) were analyzed. 
Results: The expressions of EGER, HER-2, P53 and VEGF in GC were 17.7, 17.0, 41.0 and 55.9%, 
respectively. The expressions of EGFR and P53 were positively correlated (r = 0.306, p < 0.05), while 
the expressions of VEGF and HER-2 were negatively correlated (r = -0.2, p < 0.05). The expressions of 
EGFR, HER-2 and VEGF were not related to the clinico-pathological factors (p > 0.05) while expression 
of P53 was related only to histological grade (p < 0.05). Univariate analysis showed that OS and DFS 
were longer (p < 0.05) when P53 was lowly expressed. Multiple-factor analysis revealed that histological 
grade, infiltration depth and P53 expression were independent factors that influenced DFS. 
Conclusion: These results indicate that the expression of P53, EGFR, HER2 and VEGF can be used to 
predict prognosis of GC and screening of patients’ benefits from adjuvant chemotherapy. 
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Gastric cancer (GC) is the fifth most common 
malignant disease and is the third leading cause 
of cancer deaths in both sexes worldwide [1]. In 
China, GC is currently the second most common 
cancer and second leading cause of cancer 
death [2]. Although the incidence of GC has 
declined recently, a 2016 study showed that the 
5-year survival was less than 30 % [3]. 
 
However, recent progress in research on 
recombinant humanized anti-HER2 antibody 
(Herceptin) in the treatment of HER2-positive 
expression GC has aroused considerable 
interest in prognosis-related biomarkers and GC 
sensitivity to chemotherapy [4]. Indicators of P53, 
EGFR, HER2, and VEGF. in GC have been 
extensively investigated [5]. However, not much 
is known about the predictive roles of these 
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indicators in adjuvant chemotherapy after GC 
surgery. In addition, Meta-analysis has proved 
that adjuvant treatment with 5-fluorouracil (5-FU) 
after radical surgery in GC was beneficial to 
patients’ survival [6]. 
 
The present study was designed to evaluate the 
expression of P53, EGFR, HER2 and VEGF in 
GC patients who received adjuvant treatment of 
5-FU after radical surgery. The relationship of 
these biomarkers and clinico-pathologic 





Study population  
 
One hundred and forty seven patients admitted 
to Chinese People's Liberation Army General 
Hospital (Beijing, China) with a diagnosis of 
locally advanced GC (I –IV stage), were studied. 
All the patients accepted D2 radical operation 
and adjuvant chemotherapy with 5-FU for 4 
cycles after surgery. Histological examination 
showed that the patients did not receive any neo-
adjuvant chemotherapy prior to surgery. Follow-
up was from the day of surgery to March 11, 
2010 (about 3 to 5 years), and the data were 
obtained by outpatient review or telephone 
follow-up. The present study was approved by 
the Ethical Committee of Chinese People's 
Liberation Army General Hospital (approval no. 
0718-1[H]) and was carried out in accordance 
with the Declaration of Helsinki [7]. All patients 




Disease-free survival time (DFS) was defined as 
the period from surgery to the start of tumor 
progression or the end of follow-up. Overall 
survival (OS) was defined as the time between 
surgery and death or the end of follow-up of 
patient. The patients were divided into 11 cases 
of stage I, 44 cases of stage II, 61 cases of stage 
IIIA, 25 cases of stage IIIB and 6 cases of stage 
IV according to the TNM staging criteria for 
gastric cancer Union for International Cancer 
Control (UICC) [8]. There were 124 male patients 
and 23 female patients, with age range of 31-78 
years (median 54.57 years). Histopathological 
examination showed 89 cases of 
adenocarcinoma, 26 cases of signet ring cell 
carcinoma, and 32 cases of mixed type. In 
addition, there were 36 cases of gastric fundus 
and cardia, 54 cases of gastric body, and 57 
cases of gastric antrum. Adjuvant chemotherapy 
was divided into 3 categories:  
 
Treatment prescription I (DCF, 25 cases): 
taxotere (TXT, 60 mg/m2, 1st day); cis-
Dichlorodiamine platinum (DDP, 30 mg/m2, 1st 
day to 3rd day); 5-FU [400 mg/m2, intravenous 
injection (i.v.), 1st day]; calcium folinate (CF, 200 
mg/m2, 1st day) and 5-FU [2.4 g/m2, continuous 
intravenous injection (CIV) for 48 h]. 
 
Treatment prescription II (FOLFOX-4, 90 cases): 
oxaliplatin (LOHP, 130 mg/m2, 1st day); 5-FU 
[400 mg/m2 (i.v.), 1st day]; CF, (200 mg/m2, 1st 
day); and 5-FU (2.4 g/m2, CIV for 48 h).  
 
Treatment prescription III (DOF, 10 cases): TXT 
(60 mg/m2, 1st day); LOHP (130mg/m2, 1st day); 
5-FU (400 mg/m2, i.v., 1st day); CF (200 mg/m2, 




Samples were collected from patients who 
underwent GC surgery from January 2004 to 
December 2007 at Chinese People's Liberation 
Army General Hospital (Beijing, China). Samples 
were formaldehyde-fixed and paraffin-embedded, 
and cut at a thickness of 4 μm for 
immunohistochemical staining. The following 
antibodies were used for immune-stainings: 
EGER (Leica, dilution 1:100), P53 (DAKO, 
dilution 1:100), HER-2 (DAKO, dilution 1:100), 
VEGF (ZSGB-BIO, dilution 1:200). 
Immunohistochemical staining was performed on 




EGER and HER-2 proteins were stained brown 
and located in the cell membrane: If the cell 
membrane was not stained or if the number of 
positive cells was < 10 %, the samples was rated 
(-); if the number of positive cells was ≥ 10 % and 
cell membrane was incomplete, the sample was 
rated (+); if the number of positive cells was ≥ 10 
% and the cell membrane was complete and 
lightly or moderately-stained, the sample was 
grouped as (++); when the number of positive 
cells was ≥ 10 % , and the cell membrane was 
complete and severely stained, the sample was 
rated (+++). P53 and VEGF proteins were 
stained brown and located in cell nucleus. The 
staining was divided into 4 levels on the basis of 
average percentage of positive cells in 100 cells 
under 10 high-power microscope fields. The 
mean values were designated as follows: 0 = (-), 
≤ 25 % = (+), > 25 % but ≤ 50 % = (++), > 50 % 
but ≤ 75 % = (+++) and > 75 % = (++++). All 
average values designated as (-) and (+) were 
taken as negative, while average values 
designated (++), (+++), (++++) were regarded as 
positive. 
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Statistical analysis was performed using PASW 
Statistics 18.0 software (SPSS, Inc., Chicago, 
IL). Comparison of ratings were analyzed using 
χ2 test, correlation analyses were carried out 
using Spearman’s test, while survival rate was 
calculated by Meier-Kaplan single factor analysis 
using log - rank test. Multiple factor-survival 
analysis was performed by COX regression. p < 






EGER and HER-2 proteins were located in the 
cell membrane and cytoplasm, while P53 and 
VEGF proteins were located in cell nucleus 
(Figure 1). The expressions of EGER, HER-2, 





The expressions of EGFR and P53 were 
positively correlated (r = 0.306, p < 0.05), while 
the expressions of VEGF and HER-2 were 
negatively correlated (r = -0.2, p < 0.05). 
 
Relationship between protein expression and 
clinico-pathological factors 
 
Results on Table 1 showed that the expressions 
of EGFR, HER-2, VEGF were not linked to sex, 
age, pathology, histological grade, stage of GC, 
presence of tumor thrombus, tumor size, location 
and other clinico-pathological factors (p > 0.05). 
Expression of P53 was only related to the 




Univariate analysis showed that the OS and DFS 
of the patients were longer (p < 0.05) under the 
following conditions: low expression of P53 
expression, adenocarcinoma pathology, high 
differentiation in histological grading, early stage 
GC, absence of tumor thrombus, tumor size < 5 
cm and absence of lymph node metastasis 
(Figure 2 and Table 2).  
 
COX multiple-factor analysis showed that 
histological grade, infiltration depth and P53 





Figure 1: Positive expressions of HER-2 (A), EGFR (B), P53 (C) and VEGF (D) (× 200, Two-step GC IHC 
envision methods) 
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However, pathological type, presence of tumor 
thrombus, tumor size, lymph nodes metastasis, 
and chemotherapy group had no effect on DFS. 
The risk ratio of P53 on DFS was 0.406, and 95 
% confidence interval was 0.180 - 0.918. 
Histological grade, infiltration depth, lymph node 
metastasis and P53 expression were 
independent factors that influenced OS. 
However, pathological type, presence of tumor 
thrombus, tumor size and chemotherapy group 
had no effect on OS. The risk ratio of P53 on OS 
was 0.548, and 95 % confidence interval was 
0.325 - 0.924 (Table 3). 
 
 
Table 1: Correlation between expression of EGFR, P53, HER-2, VEGF and clinico-pathological characteristics of 
GC 
 
Variable Positive rate (%) EGFR P53 HER-2 VEGF 
Gender     
Male（124） 23 (88.5) 51 (86.4) 24 (96.0） 59 (83.1) 
Female（23） 3 (11.5) 8 (13.6) 1 (4.0) 12 (6.9) 
Age (years)        
≤ 60 (101) 17 (65.4) 41 (69.5) 15 (60.0) 47 (66.2) 
> 60 (46) 9 (34.6) 18 (30.5) 10 (40.0) 24 (33.8) 
Pathological stage     
Adenocarcinoma (89) 17 (65.4) 36 (61.0) 18 (72.0) 43 (60.6) 
Signet-ring cell  
carcinoma (26) 
4 (15.4) 10 (16.9) 4 (16.0) 10 (14.1) 
Mixed type (32) 5 (19.2) 13 (22.0) 3 (12.0) 18 (25.4) 
Histological grade     
Well to moderate (26) 5 (19.2) 6 (10.2)a 5 (20.0) 13 (18.3) 
Poor (121) 21 (80.8) 53 (89.8) 20 (80.0) 58 (81.7) 
Stage     
I (11) 3 (11.5) 6 (10.2) 3 (12.0) 8 (11.3) 
II (44) 8 (30.8) 14 (23.7) 7 (28.0) 17 (23.9) 
III (86) 15 (57.7) 37 (62.7) 15 (60.0) 42 (59.2) 
IV (6) 0 (0) 2 (3.4) 0 (0) 4 (5.6) 
Size (cm)     
T ≤ 5 (87.0) 16 (64.0) 33 (57.9) 17 (68.0) 46 (68.7) 
T > 5 (55.0) 9 (36.0) 24 (42.1) 8 (32) 21 (31.3) 
Cancer embolus      
Negative (103) 20 (76.9) 41 (69.5) 17 (68.0) 46 (67.6) 
Positive (41) 6 (23.1) 18 (30.5) 8 (32) 22 (32.4) 




 Figure 2: Univariate analysis of DFS and OS on expression of P53 
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Table 2: Univariate analysis of different clinico-pathological factors 
 
Variable Median disease-free survival time (MDFS) P-value 
Median overall survival 
time (MOS) P-value 
P53  0.050  0.008 
Negative 47 ± 7.063  66  
Positive 24 ± 5.499  30 ± 4.270  
Pathologic stage  0.000  0.000 
Adenocarcinoma  59 ± 7.895  Not available  
Signet-ring cell 
carcinoma 
17 ± 1.530  24 ± 3.739  
Mixed type 40 ± 4.778  50 ± 9.964  
Histological grade  0.033  0.006 
Well to moderate  Not available  Not available  
Poor  30 ± 6.057  47 ± 9.858  
Depth of invasion  0.000  0.001 
T1 - T2 Not available  Not available  
T3 - T4 30 ± 5.490  47 ± 7.572  
Lymphatic involvement  0.000  0.005 
Negative Not available  Not available  
Positive 29 ± 4.717  44 ± 8.832  
Stage  0.000  0.000 
I  Not available  Not available  
II  Not available  Not available  
III  22 ± 4.319  30 ± 6.306  
IV 21 ± 6.859  24 ± 4.899  
Size (cm)  0.001  0.002 
T ≤ 5  Not available  Not available  
T > 5  22 ± 4.634  30 ± 10.429  
Cancer embolus   0.055  0.047 
Negative (103) 50 ± 8.478  66 ± 9.923  
Positive (41) 24 ± 6.701  31 ± 7.468  
 
Table 3: Multivariate analysis of different clinico-pathological factors 
 
Variable Recurrent risk 95%  
Confidence 
interval 
Survival risk 95%  Confidence 





Histological grade 0.026 1.782 1.275 – 2.492 0.026 0.350 0.138 – 0.885 
Depth of invasion 0.017 2.650 1.188 – 5.915 0.008 0.067 0.009 – 0.488 
P53 0.030 0.406 0.180 – 0.918 0.024 0.548 0.325 – 0.924 




P53 is a tumor suppressor gene located on 
17p13.1 chromosome. It is highly correlated with 
human tumors. The wild-type protein of P53 has 
a half-life of about 20 - 30 min, and mutant P53 
protein has been cetected by conventional 
immunohistochemical methods [9,10]. Lazăr et al 
analyzed 61 patients with GC,  and the results 
showed that the expression of P53 was 41 % 
[11]. In that study [11], the five-year survival rate 
for patients with P53 over-expression was 8 %, 
while for patients with low-expression of P53, the 
five-year survival rate was 22.2 % (p = 0.0326). 
In the present study, expression of P53 was 41 
%, and the expression was related to histological 
grade.  
 
Studies by Geng et al [12] indicated that GC 
patients with P53 over-expression manifested 
significant resistance to 5-FU, Adriamycin and 
hydroxycamptothecine. In the present study, 
patients with low-expression of P53 did better 
than those who received priority adjuvant 
chemotherapy of 5-FU after surgery. 
 
EGFR and HER-2, members of the family of 
epidermal growth factor receptors, are type I 
receptor tyrosine kinase. The binding of ligands 
to the receptors activates the intracellular 
signaling pathways, leading to proliferation of cell 
division differentiation [13,14]. EGFR is highly 
expressed in a variety of malignant tumors, 
where it promotes angiogenesis, tumor cell 
proliferation, adhesion, invasion and metastasis, 
while inhibiting tumor cell apoptosis [15]. HER-2 
gene is located on 17q21 chromosome, and 
studies have shown that it is expressed 6 - 35 % 
in GC [16]. Results obtained in the present study 
revealed that although there is gene homology in 
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the two receptors, their expressions in GC were 
independent. However, further studies using a 
larger sample size are needed to verify the 
clinical relevance of these two genes in GC. 
 
VEGF gene is located on 6p21.3 chromosome, 
and is composed of seven members: VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, VEGF-E, PIGF-1 
and PIGF-2 [17]. VEGF is highly expressed in 
most of human malignant tumors; it promotes 
endothelial cell proliferation and increases 
vascular permeability [18]. In the present study, 
the expression of VEGF was 55.9 %, which 
indicated that the VEGF expression can be used 




The results obtained in the present study strongly 
suggest that the expressions of P53, EGFR, 
HER2 and VEGF could be used for evaluating 
the prognosis of GC and screening patients’ 








Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them.  
 
Open Access  
 
This is an Open Access article that uses a fund-
ing model which does not charge readers or their 
institutions for access and distributed under the 
terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/ 
4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 




1. He PWS, Zhang X, Gao Y, Niu W, Dong N, Shi X, Geng 
Y, Ma Q, Li M,Jiang B et al. Tspan5 is an independent 
favourable prognostic factor and suppresses tumour 
growth in gastric cancer. Oncotarget 2016; 7(26): 
40160-40173. 
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, 
Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. 
CA Cancer J Clin 2016; 66((2): 115-132. 
3. Yu J, Zhang Y, Leung LH, Liu L, Yang F, Yao X. Efficacy 
and safety of angiogenesis inhibitors in advanced 
gastric cancer: a systematic review and meta-analysis. 
Hematol Oncol 2016; 9(1): 111. 
4. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, 
Denney DW Jr, Leahy DJ. Structure of the extracellular 
region of HER2 alone and in complex with the Herceptin 
Fab. Nature 2003; 421(6924): 756-760. 
5. Vosmik M, Laco J, Sirak I, Beranek M, Hovorkova E, 
Vosmikova H, Drastikova M, Hodek M, Zoul Z, Odrazka 
K, et al. Prognostic significance of human papillomavirus 
(HPV) status and expression of selected markers 
(HER2/neu, EGFR, VEGF, CD34, p63, p53 and 
Ki67/MIB-1) on outcome after (chemo-) radiotherapy in 
patients with squamous cell carcinoma of uterine cervix. 
Pathol Oncol Res 2014; 20(1): 131-137. 
6. GASTRIC (Global Advanced/Adjuvant Stomach Tumor 
Research International Collaboration) Group, Paoletti X, 
Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, 
Rougier P, Sakamoto J, Sargent D, et al. Benefit of 
adjuvant chemotherapy for resectable gastric cancer: a 
meta-analysis. JAMA 2010; 303(17): 1729-1737. 
7. Helsinki Do. The 59th World Medical Association. 2008. 
8. Mullaney PJ, Wadley MS, Hyde C, Wyatt J, Lawrence G, 
Hallissey MT, Fielding JW. Appraisal of compliance with 
the UICC/AJCC staging system in the staging of gastric 
cancer. Union Internacional Contra la 
Cancrum/American Joint Committee on Cancer. Br J 
Surg 2002; 89(11): 1405-1408. 
9. Imai S, Kiyozuka Y, Nishimura H, Iwanaga S, Murakami 
F, Imamura K, Noda T, Haga S, Yakushiji M. 
Overexpression of the tumor-suppressor gene p53 in 
human ovarian tumor-tissues and its correlation with 
clinical stage. Int J Oncol 1994; 4(5): 1097-1103. 
10. King JC, Lu QY, Li G, Moro A, Takahashi H, Chen M, Go 
VL, Reber HA, Eibl G, Hines OJ. Evidence for activation 
of mutated p53 by apigenin in human pancreatic cancer. 
Biochim Biophys Acta 2012; 182(2): 593-604. 
11. Lazăr D, Tăban S, Sporea I, Dema A, Cornianu M, Lazăr 
E, Goldiş A, Raţiu I, Vernic C. The immunohistochemical 
expression of the p53-protein in gastric carcinomas. 
Correlation with clinicopathological factors and survival 
of patients. Rom J Morphol Embryol 2010; 51(2): 249-
257. 
12. Geng M, Wang L, Liu X, Cao Y. Relationship between 
Expression of P53,P16 and Chemosensitivity in Gastric 
Carcinoma. J Med Res 2010; 39(6): 79-81. 
13. Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, 
Majumdar AP. Epidermal growth factor receptor 
(EGFR)-related protein inhibits multiple members of the 
EGFR family in colon and breast cancer cells. Mol 
Cancer Ther 2005; 4(3): 435-442. 
Wen et al 
Trop J Pharm Res, June 2017; 16(6): 1251  
 
14. Christensen JG, Schreck RE, Chan E, Wang X, Yang C, 
Liu L, Cui J, Sun L, Wei J, Cherrington JM, et al. High 
levels of HER-2 expression alter the ability of epidermal 
growth factor receptor (EGFR) family tyrosine kinase 
inhibitors to inhibit EGFR phosphorylation in vivo. Clin 
Cancer Res 2001; 7(12): 4230-4238. 
15. Lu X, Yang L, Lu C, Xu Z, Qiu H, Wu J, Wang J, Tong J, 
Zhu Y, Shen J. Molecular Role of EGFR-MAPK Pathway 
in Patchouli Alcohol-Induced Apoptosis and Cell Cycle 
Arrest on A549 Cells In Vitro and In Vivo. Biomed Res 
Int 2016; (2016): 4567580. 
16. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi 
N, Kitano S. Suppression of tumor growth in human 
gastric cancer with HER2 overexpression by an anti-
HER2 antibody in a murine model. Int J Oncol 2005; 
27(3): 681-685. 
17. Koukourakis MI, Papazoglou D, Giatromanolaki A, 
Bougioukas G, Maltezos E, Sivridis E. VEGF gene 
sequence variation defines VEGF gene expression 
status and angiogenic activity in non-small cell lung 
cancer. Lung Cancer 2004; 46(3): 293-298. 
18. Chen YH, Pan SL, Wang JC, Kuo SH, Cheng JC, Teng 
CM. Radiation-induced VEGF-C expression and 
endothelial cell proliferation in lung cancer. Strahlenther 
Onkol 2014; 190(12): 1154-1162. 
 
